78:
Since the development of the PRIMUS, it has been translated into several languages including
Canadian English and French, French, German, Italian, Spanish, Swedish, US English, Australian and New Zealand English and US Spanish. This has allowed researchers to conduct studies for specific populations,
87:
The PRIMUS has been utilized in clinical trials which assess the efficacy of a treatment or medication. If a patient's score on the PRIMUS changes after a trial has taken place, it is inferred that the trial has had an effect on the patient's quality of life. PRIMUS has been used to assess the
373:
Ziemssen, T.; Meergans, M.; Vollmar, P.; Kempcke, R; Tracik, F.; van Lokven, T. (October 2012). "Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in
Germany (PANGAEA)".
69:
response options. Each scale has a total score which ranges from 0 to 22. The activity scale is based on 15 statements describing tasks. Patients are asked to rate their ability to perform these tasks on a scale from 1 to 3. The total score of the activities section ranges from 0 to 30.
216:
McKenna, Stephen P.; Doward, Lynda C.; Twiss, James; Hagell, Peter; Oprandi, Nadia C.; Fisk, John; Grand'Maison, Francois; Bhan, Virender; Arbizu, Txomin; Brassat, David; Kohlmann, Thomas; Meads, David M.; Eckert, Benjamin J. (December 2010).
471:
Maurer, M; Ortler, S; Baier, M; Meergans, M; Scherer, P; Hofmann, WE; Tracik, F. (2012-10-15). "Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients".
64:
The measure has three scales: quality of life, symptoms and activity limitations, which are designed to be used together or as standalone measures. The QoL and symptom scales are based on simple statements with
442:"Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod"
330:
Karampampa, Korinna; Gustavsson, Anders; Miltenburger, Carolin; Eckert, Benjamin (2012). "Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five
European countries".
410:
49:
The measure contains an assessment of quality of life, activity limitations and symptoms. A higher score on any or all of these scales indicates a lower quality of life due to the disease.
411:"Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)"
17:
418:
116:
Doward, LC; McKenna, S.P.; Meads, D.M.; Twiss, J; Eckert, BJ (2009). "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)".
440:
Cascione, Mark; Wynn, Daniel; Agashivala, Neetu; McCague, Kevin; Pestreich, Linda; Schofield, Lesley; Kim, Edward; Barbato, Luigi (2013).
285:
531:
521:
441:
415:
5th Joint triennial congress of the
European and Americas Committees for Treatment and Research in Multiple Sclerosis
526:
58:
32:
164:"Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS)"
286:"Use of the PRIMUS scale to assess quality of life in a Spanish population of multiple sclerosis patients"
18:
Knowledge talk:Articles for creation/The
Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS)
61:, the PRIMUS was developed in order to provide a more holistic view of the impact of MS on a patient.
66:
219:"International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS)"
497:
391:
355:
141:
43:
489:
347:
305:
240:
195:
133:
481:
383:
339:
297:
230:
185:
175:
125:
39:
190:
163:
515:
395:
235:
218:
35:
359:
501:
258:
145:
93:
301:
162:
Twiss, James; Doward, Lynda C.; McKenna, Stephen P.; Eckert, Benjamin (2010).
89:
485:
387:
343:
129:
180:
493:
351:
309:
244:
199:
137:
409:
T., van Lokven; Kempcke, R.; Ziemssen, T.; Meergans, M. (2011-10-20).
57:
First published in 2009 by Galen
Research and funded by
29:
Patient
Reported Outcome Indices for Multiple Sclerosis
8:
417:. Amsterdam, the Netherlands. Archived from
234:
189:
179:
111:
109:
211:
209:
157:
155:
105:
7:
168:Health and Quality of Life Outcomes
284:Hernandez, M.A.; Mora, S. (2013).
25:
236:10.1111/j.1524-4733.2010.00767.x
31:(PRIMUS) is a disease specific
1:
302:10.1016/j.nrleng.2012.06.003
548:
118:Multiple Sclerosis Journal
79:such as Spain and Europe.
486:10.1177/1352458512463481
388:10.1177/1352458512459019
344:10.1177/1352458512441566
130:10.1177/1352458509106513
59:Novartis Pharmaceuticals
33:patient-reported outcome
181:10.1186/1477-7525-8-117
42:(QoL) of patients with
53:History and properties
259:"Measures Database"
38:which measures the
532:2009 introductions
522:Multiple sclerosis
474:Multiple Sclerosis
376:Multiple Sclerosis
332:Multiple Sclerosis
263:Galen-Research.com
44:multiple sclerosis
74:International use
16:(Redirected from
539:
506:
505:
468:
462:
461:
459:
457:
437:
431:
430:
428:
426:
406:
400:
399:
370:
364:
363:
327:
321:
320:
318:
316:
281:
275:
274:
272:
270:
265:. Galen Research
255:
249:
248:
238:
213:
204:
203:
193:
183:
159:
150:
149:
124:(9): 1092–1102.
113:
83:Clinical studies
21:
547:
546:
542:
541:
540:
538:
537:
536:
527:Quality of life
512:
511:
510:
509:
470:
469:
465:
455:
453:
439:
438:
434:
424:
422:
408:
407:
403:
372:
371:
367:
329:
328:
324:
314:
312:
283:
282:
278:
268:
266:
257:
256:
252:
223:Value in Health
215:
214:
207:
161:
160:
153:
115:
114:
107:
102:
85:
76:
55:
40:quality of life
23:
22:
15:
12:
11:
5:
545:
543:
535:
534:
529:
524:
514:
513:
508:
507:
480:(5): 631–638.
463:
432:
401:
365:
322:
296:(6): 340–347.
276:
250:
229:(8): 946–951.
205:
151:
104:
103:
101:
98:
84:
81:
75:
72:
54:
51:
24:
14:
13:
10:
9:
6:
4:
3:
2:
544:
533:
530:
528:
525:
523:
520:
519:
517:
503:
499:
495:
491:
487:
483:
479:
475:
467:
464:
451:
447:
443:
436:
433:
425:September 10,
421:on 2013-11-08
420:
416:
412:
405:
402:
397:
393:
389:
385:
381:
377:
369:
366:
361:
357:
353:
349:
345:
341:
337:
333:
326:
323:
311:
307:
303:
299:
295:
291:
287:
280:
277:
264:
260:
254:
251:
246:
242:
237:
232:
228:
224:
220:
212:
210:
206:
201:
197:
192:
187:
182:
177:
173:
169:
165:
158:
156:
152:
147:
143:
139:
135:
131:
127:
123:
119:
112:
110:
106:
99:
97:
95:
91:
82:
80:
73:
71:
68:
62:
60:
52:
50:
47:
45:
41:
37:
36:questionnaire
34:
30:
19:
477:
473:
466:
454:. Retrieved
449:
445:
435:
423:. Retrieved
419:the original
414:
404:
379:
375:
368:
335:
331:
325:
313:. Retrieved
293:
289:
279:
267:. Retrieved
262:
253:
226:
222:
174:(117): 117.
171:
167:
121:
117:
94:rivastigmine
88:efficacy of
86:
77:
63:
56:
48:
28:
26:
338:(2): 7–15.
67:dichotomous
516:Categories
382:(4): 222.
290:Neurologia
100:References
90:fingolimod
456:9 October
446:Neurology
396:208625075
315:8 October
269:8 October
494:23069874
360:36736082
352:22623122
310:23067780
245:20667058
200:20937112
138:19556315
502:6838286
191:2964544
146:7459469
500:
492:
394:
358:
350:
308:
243:
198:
188:
144:
136:
498:S2CID
392:S2CID
356:S2CID
142:S2CID
490:PMID
458:2013
427:2013
348:PMID
317:2013
306:PMID
271:2013
241:PMID
196:PMID
134:PMID
92:and
27:The
482:doi
452:(1)
384:doi
340:doi
298:doi
231:doi
186:PMC
176:doi
126:doi
46:.
518::
496:.
488:.
478:19
476:.
450:80
448:.
444:.
413:.
390:.
380:18
378:.
354:.
346:.
336:18
334:.
304:.
294:28
292:.
288:.
261:.
239:.
227:13
225:.
221:.
208:^
194:.
184:.
170:.
166:.
154:^
140:.
132:.
122:15
120:.
108:^
96:.
504:.
484::
460:.
429:.
398:.
386::
362:.
342::
319:.
300::
273:.
247:.
233::
202:.
178::
172:8
148:.
128::
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.